Nu Skin Enterprises, Inc. (NUS)

The investment case for Nu Skin is currently broken by a severe multi-year structural decline. The stock has lost nearly 81% of its value over the last nine years, with four consecutive years of negative annual returns ending in a sharp drop. This is not a temporary setback; the market has consistently punished the business, driving the price from highs above $77 to sub-$10 levels. Fundamentals confirm this deterioration: revenue is contracting by 12%, earnings have collapsed by nearly 98%, and the company trades at a fraction of its book value, reflecting deep concerns about its competitive position and cash generation capabilities. While the current 4.68% dividend yield looks attractive on paper, it is a trap; the payout ratio is barely 22%, meaning the company retains almost all earnings, yet the share count dilution and lack of growth suggest the dividend is not sustainable at this level without further cuts. The options market agrees with the bearish thesis, with heavy positioning in downside protection indicating that smart money expects further pain. The statistical forecast models also lean negative, reinforcing the view that the short-term trend is down. There is no evidence of a turnaround in the data provided; the business is shrinking, the stock is falling, and the options flow is defensive.